Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
1. A conjugate of a cell penetrating carrier peptide and a heterologous active ingredient, wherein the carrier peptide is 20 amino acids in length and is the amino acid sequence of SEQ ID NO: 121, or the carrier peptide is 20 amino acids in length and has at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 121 and maintains cell penetrating ability.
2. The conjugate according to claim 1 , wherein the active ingredient is at least one selected from protein, nucleic acid, peptide, lipid, glycol-lipid, mineral, sugar, nanoparticle, biological products, contrast agent, drugs and chemical compounds.
3. The conjugate according to claim 2 , wherein the active ingredient is a cytokine, antibody, fragment of antibody, therapeutic enzyme, soluble receptor or ligand.
4. The conjugate according to claim 2 , wherein the contrast agent is selected from a group consisting of radiopaque contrast agent, paramagnetic contrast agent, superparamagnetic contrast agent and CT contrast agent.
5. The conjugate according to claim 2 , wherein the contrast agent is based on iron.
6. The conjugate according to claim 5 , wherein the contrast agent is a ferrocene carboxylate.
7. The conjugate according to claim 1 , wherein the carrier peptide and the active ingredient are combined via a covalent bond, selectively mediated by a linker, wherein the active ingredient and the linker are heterologous to the carrier peptide.
8. The conjugate according to claim 1 , wherein the carrier peptide and the heterologous active ingredient are combined via non-covalent bond.
9. A contrast agent comprising a conjugate of any one of claims 1 , 2 - 8 , and 3 .
10. A composition comprising the conjugate according to claim 1 .
11. The composition according to claim 10 wherein the composition is selected from the group consisting of a pharmaceutical composition, a cosmetic composition, and a health food composition.
12. A cell penetrating carrier peptide, wherein the carrier peptide is 20 amino acids in length and is the amino acid sequence of SEQ ID NO: 121, or is the carrier peptide that is 20 amino acids in length and having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 121 and maintains cell penetrating ability.
13. A polynucleotide that encodes the cell penetrating peptide according to claim 12 , wherein upon expression of the polynucleotide the carrier peptide that is 20 amino acids in length and is the amino acid sequence of SEQ ID NO: 121, or the carrier peptide is 20 amino acids in length and having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 121 and maintains cell penetrating ability is produced.
14. A vector that comprises the polynucleotide according to claim 13 .
15. A transformed cell that comprises the vector according to claim 14 .
16. A method of treating a subject having a mitochondrial-related disease or disorder comprising administering to the subject a pharmaceutical composition comprising the conjugate of claim 1 .
17. The method of claim 16 , wherein the pharmaceutical composition is administered though oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, in the bone marrow, epidural, or subcutaneous means.
18. The method of claim 16 , wherein the pharmaceutical composition comprises additives selected from the group consisting of diluents, excipients, lubricants, binders, disintegrants, buffers, dispersants, surfactants, coloring agents, aromatics or sweeteners.